AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT01277926
- Locations
- 🇧🇷
Research Site, Ribeirao Preto, Brazil
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
Completed
- Conditions
- Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
- Interventions
- Drug: Risk of selected safety events
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7200
- Registration Number
- NCT01276275
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug InteractionLaymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01276262
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion
Phase 1
Withdrawn
- Conditions
- Healthy
- Interventions
- Drug: [14C]-AZD9742
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01275781
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1849
- Registration Number
- NCT01275794
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication
Completed
- Conditions
- High Blood Pressure
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2013-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1501
- Registration Number
- NCT01274494
Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics
Completed
- Conditions
- Asthma
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01273363
- Locations
- 🇷🇺
Research Site, Ufa, Russian Federation
Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- COPD
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2011-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1268
- Registration Number
- NCT01266395
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
Withdrawn
- Conditions
- Dyslipidemia
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1064
- Registration Number
- NCT01265836
Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT01265654
- Locations
- 🇨🇿
Research Site, Znojmo, Czech Republic